Skip to content
Homepage
Author:
Tectonic Therapeutic
Posted Date:
June 10, 2026
Tectonic Therapeutic Completes Enrollment in TX45 APEX Phase 2 Clinical Trial in PH-HFpEF Patients
Tectonic Therapeutic
June 10, 2026
Tectonic Therapeutic Announces First Quarter 2026 Financial Results and Recent Business Highlights
Tectonic Therapeutic
May 7, 2026
Tectonic Therapeutic Appoints Jessica Chutter to Board of Directors
Tectonic Therapeutic
April 23, 2026
Tectonic Therapeutic to Participate in March Investor Conferences
Tectonic Therapeutic
March 2, 2026
Tectonic Therapeutic Announces Fourth Quarter and Full Year 2025 Financial Results and Recent Business Highlights
Tectonic Therapeutic
February 26, 2026
Tectonic Therapeutic Appoints François Nader, M.D., as Chair and Independent Director of the Board
Tectonic Therapeutic
February 23, 2026
Tectonic Therapeutic to Host Virtual KOL Event and Discussion of TX2100, a Novel Approach for the Treatment of Hereditary Hemorrhagic Telangiectasia, on February 24, 2026
Tectonic Therapeutic
February 11, 2026
